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Hepatocellular carcinoma (HCC) 
• Liver transplantation 
– Offer best survival 
– May exceed liver transplant criteria 
• Milar criteria and UCSF criteria 
– Lack of liver graft 
 Mazzaferro V et al. N Engl J Med 1996 
Yao FY et al. Hepatology 2001 
• Liver resection  
– Gold standard 
– Depends on 
• Anatomical location 
• Major vessel involvement 
• Multifocality 
• Liver function 
• Presence of distant metastasis 
• Low rate tumor resectability ~ 20% - 37% 
 Fong Y et al. Ann Surg 1999 
Poon RT et al. Ann Surg 2002 
• Radiofrequency ablation (RFA) 
– Most ideal for smaller size tumor 
• Best < 3cm 
• Safe and effective up to 8 cm in size 
– But higher recurrence rate 
 
 Poon RT et al. Arch of Surg. 2004 
Multifocal and bilobar HCC 
• Transarterial chemoembolisation (TACE) 
– Unresectable multifocal HCC 
– Palliative in nature 
 
 
Lo CM et al. Hepatology 2002 
Forner A et al. Semin Liver Dis 2010 

  
 
 
 


  
 
 
 
 
Multifocal and bilobar HCC 
• Liver resection 
– Remove the largest tumor bulk 
• RFA 
– Target lesions in the liver remnant 
– Achieve complete ablation 
Aim 
• Compare the result of combined major 
hepatectomy and RFA with major 
hepatectomy alone for bilobar multifocal HCC 
 
 
 
 
Materials and methods 
• Retrospective review from Jan 2001 to Dec 2013 
– Bilobar involvement 
– Multifocal diseases 
– Major liver resection + RFA vs major resection alone 
• Patient selection 
– Baseline characteristics 
• Matched by propensity score matching in a ratio of 1:2 
– Number of tumor nodules 
– Bilobar disease 
– Size of the tumor 
– Microvascular invasion 
– Age 
– Sex 
– Child Pugh Grading 
– TMN 7th edition staging 
Surgical technique 
• Intraoperative ultrasound to confirm tumor 
location 
• Anatomical resection for largest group of 
tumor with clear resection margin 
• RFA for smaller lesions in the liver remnant 
aiming for complete tumor ablation 
 
 
Follow up and monitoring 
• 3 – monthly in the first year and quarterly 
thereafter if no recurrence 
• CT or MRI 1 month after hepatectomy 
• Every 3 – 4 months in the first year 
• Every 6 months in subsequent years 
 
Statistical analysis 
• Continuous variables  
– Median (interquartile range) 
– Mann-whitney U-test 
• Categorical variables 
– χ2 test or Fisher’s exact test  
• In-hospital death 
– Death while patient was in hospital after hepatectomy 
• Clavien –Dindo classifications 
• Kaplan-Meier method 
– Overall survival and disease-free survival 
 
 
 
Results 
P-value of comparing  
patients’ characteristics  
of two groups  
Matched - RFA & major resection group (n=16)  
vs. 
Major resection alone (n=32) 
1. Microvascular invasion 0.527 
2. Number of tumor nodules 0.18 
3. Size of the tumor (length) 0.965 
4. Bilobar involvement 1 
5. Age 0.784 
6. Sex  1 
7. TMN 7th staging 1 
8. Child Pugh Grade 1 
Comparable confounding factors All 8 
Patients’characteristics RFA & resection group (n=16) Resection (n=32) P-value 
Age [Median (Range)] 59 (34-76) 58.5 (27-74) 0.784 
Sex [Male: Female] 13:3 25:7 1 
Hepatitis B (positive)  15 (93.8%) 29 (90.6%) 1 
Comorbid disease [yes (%)] 
  
Heart 
Lung  
Renal 
DM 
Gastrointestinal 
5 (31.3%) 
  
4 (25%) 
- 
- 
4 (25%) 
1 (6.3%) 
9 (28.1%) 
  
8 (25%) 
- 
- 
4 (12.5%) 
1 (3.1%) 
1 
  
1 
- 
- 
0.494 
1 
Child Pugh Grade 
   A 
   B  
  
15 (93.8%) 
1 (6.3%) 
  
30 (93.8%) 
2 (6.3%) 
1 
Pre-op ICG % 12.7 (3-34.9) 11.45 (4.1-29.9) 0.152 
Ascites  
Absent 
  
16 (100%) 
  
32 (100%) 
- 
MELD 7.8 (6-18) 7.5 (6-12) 0.25 
No. of tumour nodules [Yes (%)] 
2 
3 
4 
5 
6 
Multiple 
  
4 (25%) 
4 (25%) 
2 (12.5%) 
1 (6.3%) 
1 (6.3%) 
4 (25%) 
  
15 (46.9%) 
5 (15.6%) 
1 (3.1%) 
0 (0%) 
0 (0%) 
11 (34.4%) 
0.18 
Preoperative liver function 
Patients’characteristics  RFA & resection 
group (n=16) 
Resection  
(n=32) 
P-value 
Serum Bilirubin 9 (5-57) 15 (4-33) 0.098 
Creatinine 78.5 (61-120) 81.5 (59-127) 0.694 
INR 1.1 (0.9-1.8) 1 (0.9-1.3) 0.04 
Albumin 38.5 (27-43) 40 (29-46) 0.041 
Platelet count 197 (49-615) 187 (89-483) 0.861 
AFP 205 (3-738300) 116.5 (2-530600) 0.948 
AST 61 (21-882) 66.5 (24-768) 0.71 
ALT 49 (12-187) 51.5 (12-275) 0.956 
Type of resection 
 
Patients 'characteristics 
RFA & 
resection 
group (n=16) 
Resection  
(n=32) 
P-value 
Types of resection 
Right Hepatectomy 
Right Extended Hepatectomy 
Left Hepatectomy 
Left Extended Hepatectomy 
Right Trisegmentectomy 
Left Extended Hepatectomy+Caudate lobectomy 
Right Trisegmentectomy+Caudate lobectomy 
Central Bisegmentectomy 
Left Trisegmentectomy+Caudate lobectomy 
  
4 (25%) 
3 (18.8%) 
4 (25%) 
2 (12.5%) 
2 (12.5%) 
1 (6.3%) 
0 (0%) 
0 (0%) 
0 (0%) 
  
0 (0%) 
13 (40.6%) 
0 (0%) 
6 (18.7%) 
6 (18.8%) 
1 (3.1%) 
2 (6.3%) 
2 (6.3%) 
2 (6.3%) 
0.383 
 
 
 
 
Patients 'characteristics 
RFA & resection 
group (n=16) 
Resection  
(n=32) 
P-value 
Blood loss (L) 0.87 (0.12-12.3) 0.91 (0.2-3.75) 0.954 
Blood replacement (L) 0 (0-5.47) 0 (0-1.92) 0.59 
Blood transfusion (yes, %) 4 (25%) 6 (18.8%) 0.9 
Hospital stay (days) 10.5 (4-50) 13 (4-69) 0.259 
Hospital mortality (yes, %) 1 (6.3%) 0 (0%) 0.721 
Total OT duration (mins) 
  
448.5 (254-775) 455 (231-1015) 0.991 
 
Patients 'characteristics 
RFA & resection group 
(n=16) 
Resection  
(n=32) 
P-value 
Microvascular invasion [yes (%)] 
  
11 (68.8%) 19 (59.4%) 0.527 
Pattern of recurrence [No. (%)] 
   No recurrence 
   Intrahepatic recurrence 
   Extrahepatic recurrence 
   Both recurrence 
  
4 (25%) 
7 (43.8%) 
1 (6.3%) 
4 (25%) 
  
3 (9.4%) 
15 (46.9%) 
2 (6.3%) 
12 (37.5%) 
0.511 
Non tumourous liver 
   Non-cirrhotic 
   Chronic Hepatitis 
   Cirrhotic 
  
3 (18.8%) 
2 (12.5%) 
11 (68.8%) 
  
4 (12.5%) 
12 (37.5%) 
16 (50%) 
0.198 
Differentiation [Yes (%)] 
   Well 
   Moderate 
   Poor 
   NA 
  
1 (6.3%) 
13 (81.3%) 
1 (6.3%) 
1 (6.3%) 
  
4 (12.5%) 
22 (68.8%) 
5 (15.6%) 
1 (3.1%) 
0.653 
Resection Margin [Yes (%)] 
   Not involved 
   Involved 
  
15 (93.8%) 
1 (6.3%) 
  
29 (90.6%) 
3 (9.4%) 
1 
UICC 7 staging 
IIA 
IIIA 
  
  
4 (25%) 
12 (75%) 
  
7 (21.9%) 
25 (78.1%) 
1 
Follow up duration (months) 
  
18.67 (4.53-146.7) 34.47 (3.48-182.88) 0.411 
Time to recurrence (months) 
  
7.4 (0.87-43.77) 5.4 (0.93-165.83) 0.871 
Overall survival rate 
 P=0.373 
 
RFA & resection, (n=16) 
 
Resection only, (n=32)  
 
 
       
 
Disease-free survival rate 
 
Resection alone, (n=30) 
P=0.72 
 
RFA & resection, (n=14)  
 
 
 
 
       
 
Discussion 
• Surgical resection 
– Location of the tumors 
– Liver function 
– Size of the liver remnant 
• TACE  
– Multifocal disease which is inoperable 
 
Radiofrequency ablation 
• Preferred modality of local ablation for 
unresectable liver tumors 
 
• As effective as hepatectomy for HCC < 5cm  
Poon RT et al. Ann Surg 2002 
Livraghi T et al. Radiology 2000 
Poon RT et al. Arch Surg 2004 
Chen MH et al. Radiology 2004 
 
 
• Achieve a clear resection margin and 
complete ablation of tumor 
• Safe and feasible 
– Similar blood loss, operative duration and post-
operative complications and mortalities 
• Similar overall and disease-free survival 
• Increase the operability for those patients 
who used to be declined for surgery 

• Feasibility of such aggressive management as 
long as adequate future liver remnant 
– Similar survival 
• Small scale retrospective study on selected 
group of advanced HCC patients 
Conclusion 
• Safe and feasible in selected patients 
• Similar survival with bilobar and multifocal 
HCC managed with major hepatectomy alone 
• Increase the operability 
• Implication of the staging 
• Thank you 
